Loss of heterozygosity at 11p15 and p53 alterations in malignant gliomas.
OBJECTIVE
Malignant gliomas are the most frequent primary brain tumors. Recent studies defined several genetic markers, which might characterize molecular-biological subsets of glioblastomas with prognostic implications. In the later steps of tumor-progression, deletions on chromosome 11p15 and mutations of the tumor suppressor gene p53 were determined for different malignancies. To elucidate the involvement of 11p15 deletions in the tumorigenesis of malignant gliomas, we analyzed a series of 50 glioblastomas for loss of heterozygosity (LOH).


METHODS
Paired tissue and blood samples from 50 patients with glioblastoma multiforme were included. Microsatellite markers located on 11p15.1-11p15.5 were used for LOH analysis. Additionally, mutation analysis of the tumor suppressor gene p53 was performed, which might correlate with favorable survival in glioblastomas.


RESULTS
The region 11p15.4-5 was deleted heterozygously in 28% of cases representing 15 cM. Twenty-six glioblastomas did not show allelic loss for any locus. Our data revealed close association of LOH 11p15 with p53 mutations, and survival analysis showed a trend indicating better prognosis in glioblastomas characterized by LOH 11p15.


CONCLUSIONS
In the tumorigenesis of malignant gliomas, p53 mutations and 11p15 deletions seem to indicate a genetic subset of tumors with favorable prognostic value.
Schiebe
M
M
Department of Radiooncology and Radiotherapy, Community Hospital Braunschweig, Celler Strasse 38, 38114 Braunschweig, Germany. m.schiebe@klinikum.bs.shuttle.de
Ohneseit
P
P
Hoffmann
W
W
Meyermann
R
R
Rodemann
H P
HP
Bamberg
M
M
D001932:Brain Neoplasms / Q000235:genetics* / Q000401:mortality; D002880:Chromosomes, Human, Pair 11 / Q000235:genetics*; D004273:DNA, Neoplasm / Q000235:genetics; D016158:Genes, p53; D005909:Glioblastoma / Q000235:genetics* / Q000401:mortality; D006801:Humans; D019656:Loss of Heterozygosity; D016133:Polymerase Chain Reaction; D018807:Polymorphism, Single-Stranded Conformational; D011379:Prognosis
D004273:DNA, Neoplasm